These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 15270592)

  • 1. Prescribing antiepileptic drugs: should patients be switched on the basis of cost?
    Jobst BC; Holmes GL
    CNS Drugs; 2004; 18(10):617-28. PubMed ID: 15270592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generic products of antiepileptic drugs (AEDs): is it an issue?
    Bialer M
    Epilepsia; 2007 Oct; 48(10):1825-32. PubMed ID: 17850324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes.
    Andermann F; Duh MS; Gosselin A; Paradis PE
    Epilepsia; 2007 Mar; 48(3):464-9. PubMed ID: 17346246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical effectiveness and cost-effectiveness of newer drugs for children with epilepsy. A systematic review.
    Connock M; Frew E; Evans BW; Bryan S; Cummins C; Fry-Smith A; Li Wan Po A; Sandercock J
    Health Technol Assess; 2006 Mar; 10(7):iii, ix-118. PubMed ID: 16545206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recommendations of the Italian League against Epilepsy working group on generic products of antiepileptic drugs.
    Perucca E; Albani F; Capovilla G; Bernardina BD; Michelucci R; Zaccara G
    Epilepsia; 2006; 47 Suppl 5():16-20. PubMed ID: 17239100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends in resource utilization and prescription of anticonvulsants for patients with active epilepsy in Germany from 2003 to 2013 - A ten-year overview.
    Willems LM; Richter S; Watermann N; Bauer S; Klein KM; Reese JP; Schöffski O; Hamer HM; Knake S; Rosenow F; Strzelczyk A
    Epilepsy Behav; 2018 Jun; 83():28-35. PubMed ID: 29649671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic burden associated with the use of generic antiepileptic drugs in the United States.
    Helmers SL; Paradis PE; Manjunath R; Duh MS; Lafeuille MH; Latrémouille-Viau D; Lefebvre P; Labiner DM
    Epilepsy Behav; 2010 Aug; 18(4):437-44. PubMed ID: 20580619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The clinical and economic impact of generic drugs in the treatment of epilepsy].
    Argumosa A; Herranz JL
    Rev Neurol; 2005 Jul 1-15; 41(1):45-9. PubMed ID: 15999330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The economic consequences of generic substitution for antiepileptic drugs in a public payer setting: the case of lamotrigine.
    Duh MS; Andermann F; Paradis PE; Weiner J; Manjunath R; Crémieux PY
    Dis Manag; 2007 Aug; 10(4):216-25. PubMed ID: 17718660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Generic drugs in the treatment of epilepsy].
    González de Dios J; Ochoa-Sangrador C; Sempere AP
    Rev Neurol; 2005 Dec 1-15; 41(11):676-83. PubMed ID: 16317637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticonvulsants: choices and costs. Based on a presentation by Nina Graves, PharmD, FCCP.
    Am J Manag Care; 1998 Sep; 4(9 Suppl):S463-7; discussion S468-74. PubMed ID: 10185985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A cost-effectiveness decision model for antiepileptic drug treatment in newly diagnosed epilepsy patients.
    Knoester PD; Deckers CL; Termeer EH; Boendermaker AJ; Kotsopoulos IA; de Krom MC; Keyser T; Renier WO; Hekster YA; Severens HL
    Value Health; 2007; 10(3):173-82. PubMed ID: 17532810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utilization and costs of antiepileptic drugs in the elderly: still an unsolved issue.
    Beghi M; Savica R; Beghi E; Nobili A; Garattini L
    Drugs Aging; 2009; 26(2):157-68. PubMed ID: 19220072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost minimization analysis of antiepileptic drugs in newly diagnosed epilepsy in 12 European countries.
    Heaney DC; Shorvon SD; Sander JW; Boon P; Komarek V; Marusic P; Dravet C; Perucca E; Majkowski J; Lima JL; Arroyo S; Tomson T; Ried S; van Donselaar C; Eskazan E; Peeters P; Carita P; Tjong-a-Hung I; Myon E; Taieb C
    Epilepsia; 2000; 41 Suppl 5():S37-44. PubMed ID: 11045437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population.
    Davis KL; Candrilli SD; Edin HM
    Epilepsia; 2008 Mar; 49(3):446-54. PubMed ID: 18031549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of first-line antiepileptic drug treatments in the developing world: a population-level analysis.
    Chisholm D;
    Epilepsia; 2005 May; 46(5):751-9. PubMed ID: 15857443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antiepileptic treatment nearly six times more expensive since 1990].
    Persson PM; Russom A; Tomson T
    Lakartidningen; 2003 Jan; 100(1-2):42-6. PubMed ID: 12572136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generic substitution of anti-epileptic drugs. A needed battle?
    Al-Baradie RS
    Neurosciences (Riyadh); 2008 Jul; 13(3):211-6. PubMed ID: 21063327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing healthcare cost associated with the use of enzyme-inducing and non-enzyme active antiepileptic drugs in elderly patients with epilepsy in the UK: a long-term retrospective, matched cohort study.
    Borghs S; Byram L; Chan J; Dedeken P; Logan J; Kiri V; Noack-Rink M; Patsalos PN; Thieffry S
    BMC Neurol; 2020 Jan; 20(1):7. PubMed ID: 31914953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of costs of epilepsy using an electronic practice management software in Germany.
    Noda AH; Hermsen A; Berkenfeld R; Dennig D; Endrass G; Kaltofen J; Safavi A; Wiehler S; Carl G; Meier U; Elger CE; Menzler K; Knake S; Rosenow F; Strzelczyk A
    Seizure; 2015 Mar; 26():49-55. PubMed ID: 25799902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.